Newsfeeds Archive - Spark Newswire

1 minute read

Phathom Pharmaceuticals Will Present VOQUEZNA Data At DDW 2024 Annual Meeting, Being Held May 18-21

May 15, 8:07 AM

First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA® in Non-Erosive Reflux Disease (NERD)1 New research on Erosive gastroesophageal reflux disease (GERD) demonstrating high

PHAT

2 minute read

Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday

By Avi Kapoor

February 20, 11:26 AM

U.S. stocks were mostly lower, with the Nasdaq Composite falling more than 200 points on Tuesday.

AWI

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

February 19, 1:30 PM

Gainers Applied Therapeutics (NASDAQ:APLT) stock rose 42.5% to $5.34 during Monday’s regular session. The market value of their…

AMN

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights

February 16, 1:31 PM

Gainers OneMedNet (NASDAQ:ONMD) shares rose 91.2% to $1.44 during Friday’s regular session. The market value of their outstanding…

AMN

2 minute read

Phathom Pharmaceuticals Announces VOQUEZNA Tablets For Erosive GERD And Associated Heartburn Added To Express Scripts National Formularies For Commercial Patients

By Benzinga Newsdesk

February 13, 9:07 AM

One of the largest pharmacy benefit management (PBM) companies in the United States has added VOQUEZNA (vonoprazan) tablets to its national formularies for commercial plans, effective immediately FLORHAM PARK, N.J.,

PHAT

1 minute read

“Top Pick for 2024”: Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales

By Nabaparna Bhattacharya

January 5, 2:52 PM

Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),

PCVX

3 minute read

Phathom Pharmaceuticals Announces Commercial Availability Of VOQUEZNA Tablets, A Powerful First-In-Class PCAB For The Treatment Of Erosive GERD And Relief Of Associated Heartburn

By Benzinga Newsdesk

November 28, 9:06 AM

VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA tablets

PHAT